April 22, 2025 7:56am
I Don’t Know’s on third. <Abbott & Costello>
On deck, “uncle algo and his electronic trading dwarfs” are at bat
Pre-open Indications: 3 Positive and 3 Negative
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Monday’s night’s … RegMed Investors (RMi) Closing Bell: sell-off starts the week … https://www.regmedinvestors.com/articles/13887
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The latest, WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? … https://www.regmedinvestors.com/articles/13812
Tuesday: The pre-open Dow futures are UP +0.78% or (+300 points), the S&P futures are UP +0.76% or (+39.25 points) and the Nasdaq futures are UP +0.84% or (+151.25 points)
- Stock futures rose Tuesday, 4/22 as traders looked to follow through from Monday’s session,
- European markets returned from Easter Monday on a negative note
- Asia-Pacific markets were mixed
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
- Monday: The Dow closed DOWN -971.82 points or -2.48%, the S&P closed DOWN -124.50 points or -2.36% while the Nasdaq close DOWN -415.55 points or -2.55%
- Friday was market holiday
Economic Data Docket: manufacturing survey results from the Richmond Fed, just 3 Fed president speakers
Q2- April – 7 negative and 7 positive closes
- Q1/25 – March, 10 positive and 11 negative closes
- February – 12 holiday, 11 negative and 7 positive closes
- January - 2 holidays, 1 market close, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
- Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the … econs, it is still a mix of ups, downs and just uncertainty
Although … trending tickers … MY thoughts:
Positive indications:
- Alnylam Pharmaceuticals (ALNY) closed Monday down -$1.81 after Thursday’s +4.06, Wednesday’s -$0.43 and last Tuesday’s -$9.08, with a positive +$1.86 or +0.80% pre-market.
- CRISPR Therapeutics (CRSP) closed up +$0.05 after Thursday’s -$0.01 with a positive +$0.81 or +2.14% pre-open
- uniQure NV (QURE) closed Monday up +$0.29 after Thursday +$3.61 and Wednesday’s -$0.26 with a positive +$0.54 or +4.06% pre-open
Negative Indications:
- Blueprint Medicine (BPMC) closed Monday down -$0.51 after Thursday +$2.60, Wednesday’s +0.66, and last Tuesday’s -$1.08 with a negative $1.03 or -1.22% pre-open
- Mesoblast (MESO) closed Monday down -$0.44 after Thursday’s +$0.41 with a negative -$0.28 or -2.72% pre-open
- Lenz Therapeutics (LENZ) closed up +$0.29 with a negative -$0.59 or -2.45% pre-open
The BOTTOM LINE: Market volatility and cell and gene therapy sector uncertainty have upended asset value.
- I am STILL in a RISK-ON mood! There is still a fog of uncertainty.
April ‘25: understand the “flow” of bad market and economic karma…
- 4/21 – Monday closed positive with 21 positive, 13 negative and 1 flat
- 4/18 - Friday, market closed on holiday
- 4/17 -Thursday closed positive with 25 positive, 7 negative and 3 flats
- 4/16 – Wednesday closed negative with 2 positive, 31 negative and 2 flats
- 4/14 – Tuesday closed barely positive with 17positive, 16 negative and 2 flats
- 4/13 – Monday closed positive with 23 positive, 7 negative and 5 flats
- 4/11 - Friday closed positive with 28 positive, 5 negative and 2 flats
- 4/10 - Thursday closed negative with 4 positive, 30 negative and 1 flat
- 4/9 – Wednesday closed positive with 33 positive, 1 negative and 1 flat
- 4/8 - Tuesday closed negative with 4 positive, 30 negative and 1 flat
- 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
- 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
- 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
- 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
- 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
Brace ourself for more economics and their down trending affect?
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.